Medivation, Inc. Selects ProTrials Research, Inc. to Conduct International Phase III Clinical Trials

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--ProTrials Research, Inc.TM, a leader in the clinical research organization industry, today announced Medivation, Inc. (NASDAQ:MDVN) has chosen the company to conduct separate international Phase III clinical trials for two novel treatments. ProTrials will test MDV3100 for treating prostate cancer and the investigational drug Dimebon TM as a treatment for Huntington’s disease. Due to the complex nature of these Phase III trials, Medivation again selected ProTrials as its contract research organization partner because of ProTrials’ successful past performance with the company’s Phase I, II and III trials.

Back to news